Epidermal growth factor receptor-targeted treatment strategies in advanced pancreatic cancer: Is K-RAS mutational testing ready for prime time? | springermedizin.at

Springer Medizin Österreich

nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.12.2011 | Controversy

Epidermal growth factor receptor-targeted treatment strategies in advanced pancreatic cancer: Is K-RAS mutational testing ready for prime time?

verfasst von: T. Bauernhofer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Anzeige

Vorheriger Artikel Surgical topics of interest at the 14th World Conference on Lung Cancer

Nächster Artikel The role of radiochemotherapy in the multimodal treatment of pancreatic ductal adenocarcinoma: Standard procedure or individual decision?

Titel: Epidermal growth factor receptor-targeted treatment strategies in advanced pancreatic cancer: Is K-RAS mutational testing ready for prime time?
verfasst von: T. Bauernhofer
Publikationsdatum: 01.12.2011
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2011
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-011-0302-3

Weitere Artikel der Ausgabe 4/2011

Gender and oncology: Pathological observations

Short review

Molecular oncology in lung cancer – between biomarkers and clinical application. Relevance of the Ras–Raf–MEK–ERK pathway

Review

Gender and haemato-oncology: Aspects of pharmacokinetics and pharmacodynamics

Short review

Surgical topics of interest at the 14th World Conference on Lung Cancer

Congress report

Gender aspects in haematology and oncology: Overview and own observations in lung cancer

Leading article

Gender differences in quality of life in patients with haematological malignancies

Short review